Cost of Exempting Sole Orphan Drugs From Medicare Negotiation

This cross-sectional study examines the costs of the exemption from Medicare price negotiation under the Inflation Reduction Act (IRA) for drugs approved solely for the treatment of a single rare disease.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research